Opsumit (macitentan) is a tissue-targeting Endothelin Receptor Antagonist. Endothelin Receptor Antagonists mediate a variety of deleterious effects, such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation.
Opsumit is specifically indicated for the treatment of pulmonary arterial hypertension (WHO Group I) to delay disease progression.
Opsumit is supplied as a tablet for oral administration.
Submit your review
Adverse events associated with the use of Opsumit may include, but are not limited to, the following:
urinary tract infection
The recommended dose is 10 mg once daily.